<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>87 patients underwent bone marrow transplantation (BMT) in Innsbruck between 1983 and 1992 </plain></SENT>
<SENT sid="1" pm="."><plain>81 patients were suffering from <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> and severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and six patients had advanced <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e>/<z:hpo ids='HP_0100242'>sarcoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>56% of the patients undergoing HLA-identical sibling BMT were in an advanced or refractory stage of disease at the time of BMT </plain></SENT>
<SENT sid="3" pm="."><plain>19 patients underwent autologous BMT and 5 patients received a graft from an HLA-matched unrelated donor </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were treated with standard conditioning regimens according to the underlying disease </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> A (CsA) was given prophylactically against <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) either alone or in combination with <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Probability of survival for patients transplanted in the first <z:hpo ids='HP_0011010'>chronic</z:hpo> phase of <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) was 85%, whereas the disease free survival (DFS) for patients transplanted in accelerated phase or <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> was only 40% </plain></SENT>
<SENT sid="7" pm="."><plain>DFS for <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in first complete remission and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) standard-risk (i.e., first or second complete remission) was 71% and 60%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients transplanted for non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) or <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> had refractory or advanced disease </plain></SENT>
<SENT sid="9" pm="."><plain>Probability of survival for <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients was 60% </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD &gt; grade II developed in 35% of patients undergoing HLA-identical sibling BMT (46% in the high-risk group vs. 21% in the standard-risk group) </plain></SENT>
<SENT sid="11" pm="."><plain>Main causes of <z:hpo ids='HP_0011420'>death</z:hpo> in the high-risk group were relapse (31%), severe <z:mp ids='MP_0001794'>bacterial</z:mp> or <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> (17%), interstitial <z:hpo ids='HP_0002090'>pneumonia</z:hpo> (11%) and <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (6%) </plain></SENT>
</text></document>